Naltrexone, in low doses such as 3mg to 4.5mg, has been found to boost the immune system in MS, autoimmune diseases, and central nervous system disorders. Naltrexone was FDA-approved in 1985 for the management of alcohol dependence and opioid dependence at 50mg doses.
Read more...
| Reasons taken | # of patients | Major | Moderate | Slight | None | Can’t tell | # of patients evaluated by |
|---|---|---|---|---|---|---|---|
| Slow my ALS progress | 27 |
|
|
|
|
6 | |
| Other | 5 |
|
|
2 | |||
| Fatigue | 2 |
|
1 | ||||
| Slow down ALS symptoms | 1 | 0 | |||||
| hopeful that it slows progression | 1 | 0 | |||||
| improved breathing | 1 | 0 |
Mouse over the table for more information
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
|
Doctor's advice
|
4 | 33% |
|
|
Other
|
4 | 33% |
|
|
Did not seem to work
|
2 | 17% |
|
|
Side effects too severe
|
2 | 17% |
|
|
Not indicated
|
1 | 8% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on November 21, 2009.